علاج التصلب الجلدي المنتشر المبكر ذي الإنذار السيئ

References

DOI: 10.1136/ard-2024-226430

High-intensity immunosuppression (usually including cyclophosphamide) followed by autologous HSCT may be considered for the treatment of selected patients with early dcSSc and poor prognosis, in the absence of advanced cardiorespiratory involvement.

The event-free survival analysis showed accordingly, that 74% of patients in the transplant arm remained event free at month 72 vs 47% of patients in the cyclophosphamide arm.